According to Fortune Business Insights, the worldwide idiopathic inflammatory myopathy treatment market was valued at roughly $652 million in 2018 and is forecast to climb to about $1.23 billion by 2032, translating to an annual growth rate near 4.6%. As of 2018, North America was the leading region, accounting for close to 48% of global revenue.
Idiopathic inflammatory myopathies are a set of rare autoimmune conditions that damage skeletal muscle and can also involve the lungs, joints, and skin. Historically, distinguishing between dermatomyositis and polymyositis was difficult because of how uncommon these diseases are and how much their symptoms can overlap with other disorders. The report notes that improving diagnostic technology is gradually easing this challenge, which in turn is supporting market expansion.
Growth Drivers
Two themes stand out as the report's main growth drivers. First, rising awareness of myositis and its health consequences is leading to more diagnostic testing, which naturally increases the number of recognized cases and, with it, treatment demand. Because these conditions can cause lasting disability or be fatal without proper care, that awareness carries real clinical weight. Second, a growing pipeline of new therapeutics — including biologic candidates from companies such as Immunoforge, working on a treatment for polymyositis and inclusion body myositis — is expanding the treatment options available beyond the traditional mainstays of corticosteroids and general immunosuppressants.
Get a Free Sample PDF - https://www.fortunebusinessinsights.com/enquiry/request-sample-pdf/idiopathic-inflammatory-myopathy-treatment-market-100198
Market Segmentation
By disease type, polymyositis is expected to be the fastest-growing category given how common it is relative to other myopathies and its prominence in current drug pipelines. Dermatomyositis holds the second-largest share, while inclusion body myositis also has a notable presence among therapies in development.
By treatment type, immunosuppressants are projected to grow the fastest, partly because they're often used alongside corticosteroids for more complete disease management, and partly due to their higher cost per patient. The report projects corticosteroid sales specifically reaching about $54.8 million by 2025. Intravenous immunoglobulin therapy is also gaining ground, especially for harder-to-treat or advanced cases.
By route of administration, intravenous treatments are expected to hold the largest share, largely because IV immunoglobulins and some immunosuppressants — both relatively costly — are delivered this way. Oral medications, including corticosteroids, remain important as frontline options and hold the second spot.
By distribution channel, hospital pharmacies are projected to dominate, expected to command around 62.5% of the market by 2025, since IV immunoglobulin treatments require administration by trained clinical staff. Retail pharmacies rank second, mainly serving prescription refills, while online pharmacies are expected to see the fastest growth as more patients turn to digital purchasing options.
Regional Insights
North America generated an estimated $312 million in revenue in 2018 and is expected to keep leading the market, aided by high disease prevalence, substantial healthcare spending, and continued R&D activity in the region.
Asia Pacific is projected to post the strongest overall growth, driven by rising healthcare budgets, greater diagnostic awareness, and expanding access to advanced therapies. Japan's market is expected to reach about $80.3 million by 2025, while China is forecast to grow at a robust CAGR near 7.3%.
Europe is expected to expand at roughly a 3.7% CAGR, with countries like Sweden and Germany contributing meaningfully due to relatively high disease prevalence. Latin America's growth is expected to be more modest, though Brazil's efforts to establish clinical treatment guidelines should help. The Middle East and Africa are anticipated to see steady, gradual growth tied to rising awareness and detection.
Competitive Landscape
The report describes a market shaped by a small group of established players with broad geographic reach and consistent R&D investment — particularly in intravenous immunoglobulin products — alongside a wider set of clinical-stage biotech firms developing biologic candidates. Companies named in the report include Immunoforge, Orphazyme A/S, Biotest AG, CSL Limited (CSL Behring), Grifols, Kedrion, LFB Group, Shire/Takeda, Pfizer, and Mylan. CSL Behring, Grifols, and Shire/Takeda are identified as the market's top players.
Recent developments cited include Octapharma's 2021 regulatory approvals in both the U.S. and EU for an IV immunoglobulin therapy targeting adult dermatomyositis, Corbus Pharmaceuticals' Phase 3 trial progress for a dermatomyositis treatment, and Kezar Life Sciences receiving Orphan Drug Designation for a polymyositis and dermatomyositis candidate.